Companies

Dr Reddy’s launches therapeutic equivalent of Vitamin K1 in US

Our Bureau Hyderabad | Updated on June 22, 2019 Published on June 22, 2019

Pharma major Dr Reddy’s Laboratories Ltd has launched Phytonadione Injectable Emulsion USP a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, approved by the U.S. Food and Drug Administration (USFDA).

“We’re pleased to bring this product to market for the customers and patients who will benefit from access to this medicine and who have in the past experienced supply disruptions in the market place,” said Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories in a release issued here.

The product will be an addition to the Hyderabad-based company’s injectable offering in the U.S. market. ``We continue to augment our portfolio to drive growth for the Global Hospitals segment,’’ he added.

The Vitamin K1 (Phytonadione) for Injectable Emulsion USP brand and generic had combined US sales of approximately $46.6 million for the most recent twelve months ending in April 2019 according to IQVIA Health.

Published on June 22, 2019
This article is closed for comments.
Please Email the Editor